Altamira Therapeutics Ltd. is a preclinical-stage biopharmaceutical company developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues. The company's primary focus is on its xPhore platform, which enables systemic or local delivery of RNA therapeutics such as siRNA, mRNA, and circRNA to non-liver tissues. Altamira Therapeutics operates in the biotechnology sector, specifically targeting advanced drug delivery systems…
Altamira Therapeutics Ltd. is a preclinical-stage biopharmaceutical company developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues. The company's primary focus is on its xPhore platform, which enables systemic or local delivery of RNA therapeutics such as siRNA, mRNA, and circRNA to non-liver tissues. Altamira Therapeutics operates in the biotechnology sector, specifically targeting advanced drug delivery systems for nucleic acid-based therapies.
The company generates revenue primarily through out-licensing its xPhore RNA delivery platform to pharmaceutical and biotechnology companies. Revenue is derived from licensing agreements that include upfront payments, milestone payments upon achieving preclinical and clinical development goals, and royalties on net sales of licensed products. Altamira Therapeutics also retains economic interests in divested legacy assets, such as its 49% stake in Altamira Medica AG, which manufactures and markets the Bentrio nasal spray for allergic rhinitis, though this is not a current focus of its RNA delivery strategy.
The company operates through the following segments: RNA delivery platform and legacy assets.
- RNA delivery platform: This segment encompasses the development and out-licensing of the xPhore technology for delivering siRNA, mRNA, and circRNA to extrahepatic tissues. The platform includes specialized formulations such as OligoPhore for siRNA, SemaPhore for linear mRNA, and CycloPhore for circular RNA. Altamira Therapeutics is advancing two flagship siRNA programs under this segment: AM-401 for KRAS-driven cancers and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept.
- Legacy assets: This segment includes the AM-125 nasal spray reformulation of betahistine for vertigo, which has completed a Phase 2 trial and received FDA IND clearance in June 2023. It also includes the Bentrio OTC nasal spray for allergic rhinitis, marketed through Altamira Medica AG, in which Altamira Therapeutics retains a 49% stake after divesting 51% in 2023. Bentrio is regulated as a Class II medical device by the FDA and is designed to form a protective gel layer on the nasal mucosa to bind and discharge airborne allergens and viruses.
Altamira Therapeutics holds a competitive position in the emerging field of extrahepatic RNA delivery, differentiating itself from liver-focused platforms like lipid nanoparticles and GalNAc conjugates through its ability to achieve systemic delivery to non-liver tissues with efficient cellular uptake and endosomal escape. The company faces competition from other biopharmaceutical firms and academic institutions developing RNA delivery technologies, including Acuitas Therapeutics, Entos Pharmaceuticals, Genevant Sciences, and Sirnaomics Ltd., though it believes its xPhore platform offers advantages in biodistribution, pharmacokinetics, and safety profile based on preclinical data.
The company serves pharmaceutical and biotechnology companies seeking to partner or license RNA delivery technologies for their own therapeutic programs, particularly in oncology and inflammatory/autoimmune diseases. Specific customer names are not disclosed in the filing, but the business model relies on out-licensing to industry partners rather than direct-to-consumer sales. Altamira Therapeutics also maintains an economic interest in the Bentrio business, which serves over-the-counter consumers suffering from allergic rhinitis through retail and distributor channels.